INTRODUCTION
Cellular therapy with defined populations of regulatory immune cells is emerging as a clinically viable strategy to augment or replace conventional immunosuppression in the fields of haematopoietic stem cell (HSC) transplantation, autoimmune disease and solid organ transplantation where the major driver is improved therapy and a reduction in drug toxicities.
Much of the optimism surrounding these approaches is based on data from a large number of diverse animal models which show unequivocally that cellular therapy can take advantage of endogenous regulatory mechanisms in the mammalian immune system. Phase I/II clinical trials have evaluated naturally occurring regulatory T cells (nTreg), in the context of graft-versus-host-disease (GVHD), a life-threatening complication of HSC transplantation [1] [2] [3] and in paediatric patients with new-onset Type 1 diabetes. 4 In solid-organ transplantation, an international consortium is currently seeking regulatory approval for the evaluation of several types of regulatory immune cells in living-donor kidney transplantation.
Cell types under investigation in this study will include nTreg, [5] [6] [7] Tr1 cells, 8, 9 dendritic cells, 10 and macrophages. 11, 12 Determining the persistence and tissue distribution of the administered cells is essential for assessing their immunoregulatory effects in vivo but tracking therapeutic cells presents two significant challenges. Firstly, in the majority of cases, the cellular therapy will be derived from the transplant donor in HSC transplantation, or from the recipient in the case of kidney transplantation. Thus, in most cases the cells will be autologous with the immune system of the transplant recipient and therefore invisible to normal phenotypic methods of detection such as flow cytometry. Secondly, at current planned doses, the administered cells will represent a small fraction of the recipient's endogenous regulatory immune cells adding further to the problem of detection. A solution to these two related problems would be the development of clinically acceptable (GMP) cell labelling techniques combined with a sensitive detection method, capable of detection of single cells and at very high cell detection efficiency.
Contrast agents (CA) are frequently used in conjunction with clinical magnetic resonance imaging (MRI) to enhance the quality of images. These agents typically consist of a paramagnetic metal ion, such as Gd 3+ or Fe 2+ /Fe 3+ , associated with a strong chelating ligand. 13 Gadolinium based contrast agents are a particularly attractive option for cell labelling, due to their low background levels in the human body, and indeed several studies have reported their use as cellular labels for MRI tracking studies. [14] [15] [16] However, whilst MRI is undoubtedly valuable for bulk imaging, the technique is currently incapable of providing the necessary sensitivity and spatial resolution for single cell monitoring.
Laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) is a sensitive analytical technique, widely used for mapping the distribution of elements in complex biological samples. 17 Examples include the analysis of copper and zinc in liver and kidney sections, 18, 19 the mapping of copper, zinc, iron and manganese in sections of brain tissue, [20] [21] [22] [23] [24] and the quantification of metal binding proteins in gels following electrophoretic separation of blood serum. 25 Recently, the technique has been applied to image the distribution of iodine, silver and gold in single fibroblast cells, following labelling in vitro with KI 3 and gold and silver nanoparticles respectively. 26, 27 Studies have also reported the detection of gadolinium-based contrast agents in tumour and tissue samples. [28] [29] [30] Two of these investigations involved a direct comparison between LA-ICP-MS and MRI, and demonstrated the enhanced sensitivity and spatial resolution achievable when using LA-ICP-MS.
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Although LA-ICP-MS clearly has remarkable sensitivity, application of this technique to cellular therapy depends upon cell labelling techniques that are likely to be approved for clinical use. In the current study, purified human CD4 + T cells were labelled with the contrast agents, Omniscan® (Gadolinium diethylenetriaminepentaacetic acid bismethylamide, Gd-DTPA-BMA) or Dotarem® (Gadolinium 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracarboxylic acid, Gd-DOTA) that are both in routine clinical use in magnetic resonance imaging. We demonstrate that human CD4 + T cells and highly purified naturally occurring regulatory T cells can be labelled efficiently with Gd-chelates, and that the cells can then be readily detected in mixed populations using LA-ICP-MS. Importantly, both in vitro and in vivo, the cells retain detectable label for at least 10 days. To the authors' knowledge, this is the first application of LA-ICP-MS to track single gadolinium labelled human T cells.
EXPERIMENTAL

Instrumentation and operating parameters
Analyses were performed on a sector-field ICP-MS instrument (Element 2XR, Thermo Scientific, Bremen, Germany). For solution analyses, the instrument was fitted with a cyclonic spray chamber (Glass Expansion, Victoria, Australia), a conical glass concentric nebuliser (Glass Expansion, Victoria, Australia), and a 0.25 mm I.D. probe (Elemental Scientific, Omaha, USA). For laser ablation, a UP-213 laser ablation system (Electro Scientific Industries, Cambridgeshire, UK) was coupled to the sector-field ICP-MS instrument.
The laser system was fitted with a low-volume, tear-drop shaped cell, which has been described elsewhere. 31 Helium was used as an ablation gas, at a typical flow rate of 0.6 l/min, with argon introduced through a Y-piece, at a flow rate of 0.8 l/min, after the ablation cell. The system was tuned for maximum 238 U signal intensity, whilst keeping the Th/U ratio to approximately 1, during the ablation of NIST 611 glass. Typical operating conditions are given in Table 1 .
Cell culture and labelling
Human peripheral blood mononuclear cells (PBMC) were isolated from a leukocyte cone 
Optimisation of the labelling dose and incubation time
Labelling optimisation experiments for Gd-DOTA and Gd-DTPA were carried out in parallel using cells from the same donor. Cell culture and sample preparation were performed in accordance with the procedure detailed above. Quantification of label uptake by the cell population was determined using solution based ICP-MS. For these, the relevant dilutions were made in solution before fixing the cells onto slides.
Ratios of 1:1, 1:10 and 1:100 were prepared as known samples, and a replicate of each was provided as a blind sample. Blind samples were randomised and identified with a nondescriptive character. The expected ratios of these were not disclosed to the analyst until after the analysis was completed.
In vivo and in vitro label retention
In order to demonstrate cellular retention of the label and assess its potential for cell tracking studies, a 10 day in vivo mouse study was conducted. All mouse experiments were conducted in accordance with the Animals (Scientific Procedures) Act 1986. Human peripheral blood mononuclear cells (PBMC) were isolated from leukocyte cones. The CD4 + component was isolated using the procedure described above, and these cells were labelled using the optimised labelling procedure. Following labelling, the Gd-CD4 + cells were washed extensively and recombined with the non-CD4 + PBMC component. Re-mixing with the unlabelled PMBC component was found to be necessary to ensure viability of the cells in the host. The recombined cells were then injected intraperitoneally into BALB/C Rag-/-common-γ chain mice, at a level of 5 million cells per mouse. At 3, 6, and 10 days post infusion, the spleen and blood were harvested and a peritoneal lavage was performed. The extracted cells were plated onto slides for LA-ICP-MS analysis, using the CytoSpin method described above. Flow cytometry (BD FACSCanto, BD Biosciences) was used to determine the extent of human cell reconstitution.
To estimate the degree of signal loss caused by label leakage, an in vitro label retention study was performed in parallel to the in vivo mouse experiments, using cells from the same donor. For this, the cells were washed extensively after labelling and cultured for a further period in vitro before re-washing and plating onto slides.
RESULTS AND DISCUSSION
Label uptake and optimisation Figure 1 shows the impact of increasing the dose of gadolinium chelate on the uptake of Gd by human CD4 + cells. Uptake of Gd increased in a dose-dependent manner. A quadratic fit with a low second order term fitted the data; however no plateau was reached in the dose range examined. Despite the higher uptake at 100 and 200 µl, a dose of 50 µl was chosen as the optimum (this corresponds to 1.86 and 1.96 mg Gd/ ml for Omniscan and Dotarem respectively). Volumes higher than 50 µl occupied a significant portion of the 2 ml culture medium, which could potentially cause osmotic effects. However, it should be pointed out that the cell viability was 96% or above for all doses tested.
Gadolinium uptake also increased as a function of incubation time for both complexes, as shown in Figure 1 . The highest uptake was observed after 16 hours, which was used as the standard incubation time in all subsequent experiments. Longer incubation times were not tested on the grounds that they might have a detrimental effect on cell viability. As shown later, the labelling levels achieved were more than adequate for achieving ~100% detection efficiency. A 0 hour time point was included in the study as a measure of the efficiency of the cell washing process. For this, the Gd complex was added to the well and the cells washed immediately, thereby allowing insufficient time for label internalisation.
Consequently, any Gd found in these samples was taken to be from incomplete removal of the non-internalised complex and thus represents the background in the assay. The Gd content of the 0 hour samples ranged between 5 and 20 times larger than that in the nonlabelled controls. However, this figure represents only 0.7 and 3% of the final uptake achieved using the optimised labelling conditions for Gd-DTPA-BMA and Gd-DOTA respectively. The cell washing procedure was therefore considered sufficient to enable quantification of label uptake. The optimisation experiments, shown in Figure 1 , indicated that Gd-DTPA-BMA provides higher net Gd loading than Gd-DOTA, with an average loading of 1.43 x10 8 atoms per cell observed for Gd-DTPA-BMA compared to only 9.36 x10 7 atoms
per cell for Gd-DOTA at the optimised conditions. Therefore, Gd-DTPA-BMA was used in all subsequent experiments.
It is likely that uptake of the Gd-complexes occurred predominately by pinocytosis, as has been reported for other cell lines. 34, 35 Gadolinium internalised via this route is known to localise to endosomes within the perinuclear region of the cell, 34 where subsequent detachment of Gd 3+ from its chelate may occur. 35 Dechelation is expected to be more prevalent for Omniscan than Dotarem. As shown in Figure 2 , the DTPA-BMA chelate is nonionic and has an open chain structure, hence providing less stable binding to Gd 3+ than the macrocylic, ionic DOTA chelate. 36 Dechelation is accelerated in the presence of phosphate or competing cations, 37 both of which are constituents of the cell culture media. Thus it is likely that by the 16 hour time point, a portion of the Gd in the culture media was also present as free rather than complexed Gd. Free Gd 3+ ions may be subject to a different route of uptake than the complexed form. In 1999, Cheng et al. conducted a comprehensive study into the uptake of lanthanide 3+ ions by erythrocytes. 38 Gd 3+ was found to bind initially to membrane phospholipids, followed by a transfer to membrane proteins. This process induced conformational changes in the membrane, which resulted in the formation of pores, facilitating the entry of Gd
3+
. It is possible that this mechanism may have provided an additional route for Gd uptake. Since Gd-DTPA-BMA is known to be more unstable than
Gd-DOTA, this additional route may account for the differences between Gd uptake for the two chelates, particularly at the 16 hour time point.
The data shown in Figure 1 was obtained using cells isolated from human PBMC by magnetic negative selection of CD19 + B cells and CD14 + monocytes followed by CD4
positive selection. Phenotypic analysis showed that the resultant populations were between 95-98% CD4 + T cells, but they also contained ~2-5% monocytes due to low level monocyte expression of CD4. In view of the fact that these cells are known to have very active phagocytic and pinocytic pathways, the possibility that the Gd labelling seen was due to preferential monocyte uptake could not be ruled out. To address this question, human CD4 + T cells were purified by flow sorting to purities exceeding 99%, containing <0.2% CD14 + monocytes (data not shown). The resultant populations were then labelled using the optimised Gd-DTPA-BMA protocol described above. Subsequent analysis showed a gadolinium uptake of 4.53 x10 7 atoms per cell for 99.6% pure CD4 + T cells, compared with the 1.43 x10 8 atoms per cell seen for the lower purity (~95-98%) CD4 + T cells.
Most of the initial focus on regulatory immune cell therapy cellular therapy has been and will continue to be on naturally occurring Treg (nTreg). The above data show unequivocally that populations of non-phagocytic human T cells being Table 2 , the percentage labelled as determined by LA-ICP-MS matched well with the prepared ratios with differences probably accounted for by a combination of incomplete mixing and pipetting errors. As a further test of the technique, blind ratios of labelled and unlabelled CD4 + T cells were prepared and the blinding only revealed after LA-ICP-MS analysis. As shown in Table 2 , ratios observed from the blind experiments corresponded with the expected ratios adding further confirmation to the reliability of the technique.
In vivo and in vitro label retention
In addition to detection, a second key characteristic for any label considered for in vivo cell tracking is label retention. Therefore, Gd-DTPA-BMA labelled CD4 + T cells were cultured in vitro in gadolinium-free T cell growth medium containing IL-2 and samples taken daily for LA-ICP-MS analysis. As shown in Table 3 39 These double knock-out (DKO) mice were reconstituted intra-peritoneally with 2x10 6 Gd-DTPA-BMA labelled CD4 + T cells together with 3x10 6 autologous PBMC which aid T cell reconstitution by providing essential T cell growth and survival factors. At 3, 6 and 10 days after reconstitution, the mice were killed for recovery of the peritoneal lavage, spleen and blood. Reconstitution in this model is defined as >1% human CD45 + cells in the leucocyte gate as determined by flow cytometry. 39 In agreement with previous experience of this model which showed that reconstitution of spleen and blood lags behind that of the peritoneal lavage, human cells
were not found in the spleen or blood up to day 10 (not shown). However, human CD45 + cells were readily detected in the peritoneal lavage. Example data for one of three mice harvested 6 days after cell administration is shown in Figure 5A . For comparison, the lower histogram shows an example of non-reconstitution. As shown in the lower dot plot, region P3 confirms the presence of human CD4 + T cells within the human CD45 + gate.
Aliquots of each lavage sample were plated without cell purification onto slides for LA-ICP-MS analysis. Figure 5B shows an LA-ICP-MS plot from the lavage sample in Figure 5A showing identification of 5 gadolinium labelled cells. It is notable that whilst cells analysed after in vitro culture were relatively uniform in size, those examined from the lavage samples contained significant numbers of blasting cells possibly representing T cells mounting a xenogeneic graft-versus-host response. To accommodate the larger cell diameters, the ablation spot size was increased from 25 to 30 μm. However, increasing the spot size made the selection of single cells more challenging and it is possible that some of the low signals in Figure 5B were caused by slight overlap of the ablated region with the edges of neighbouring labelled cells. To account for the low signals, a threshold value was set at 5% of the average signal intensity of the corresponding in vitro sample. Signals below this threshold were not included in the % labelled count. Table 4 (Table 4) . Thus, both the in vitro and the in vivo data indicate that, when labelled with Gd-DTPA-BMA, human CD4 + T cells retain a detectable gadolinium level for at least 10 days.
Nephrogenic systemic fibrosis
The potential use of gadolinium labelling for tracking immune cellular therapies would depend on a favourable toxicity profile for the label itself and while Gd-chelates are widely used in clinical MRI, one significant complication of in vivo gadolinium administration is Nephrogenic systemic fibrosis (NSF). Although rare, this condition is potentially fatal and is characterised by "extensive thickening and hardening of the skin". 41 Studies on patients with impaired renal function have found a link between the intra-venous administration of gadolinium chelates and the onset of NSF. 42, 43 Consequently, the administration of gadolinium contrast agents for MRI imaging is contra-indicated in patients with renal impairment. Thus, any proposed use of gadolinium labelling should be treated with caution, particularly since regulatory approval is currently being sought for cellular therapy in renal transplant patients. 44 However, it is important to note that at the anticipated cell doses used in this study (3x10 6 /kg patient body weight), the Gd exposure from the proposed labelling method is dramatically lower than that received during a typical MRI scan. When taking into account the average cell uptake shown in the current study of ~27 fg and the anticipated cell dose, the likely Gd exposure from cell labelling is ~81 ng/kg. This is over 100,000 times lower than the 15.2 mg/kg dose employed for MRI imaging (Omniscan is typically administered at a level of 0.2 ml per kg patient weight; the formulation contains 287 mg/ml
Gd-DTPA-BMA, which equates to 76.1 mg/ml Gd). The risk is further minimised due to the route of administration, since for cell labelling, the gadolinium chelates are essentially compartmentalised inside the cells rather than being introduced into the systemic circulation. Gd/ ml) was used for cell labelling, which was based on sufficiency for cell tracking.
CONCLUSION
However, since Gd cell content decreases with each cell division, it may be beneficial to increase this dose when performing longer term tracking experiments. Doses of up to 200 µl Omniscan (6.72 mg Gd/ ml) were utilised during the solution study without noticeable impact on cell viability. Assessment of the effect of Gd-DTPA-BMA on the regulatory function of T cells will be the subject of a future study. showing the presence of 6 Gd labelled cells. Small peaks below the threshold value (red line) were not included in the % labelled count.
